Since human IgG4 can activate mouse macrophages and induce ADCC, it is possible that nivolumab activates mouse macrophages, resulting in the subsequent killing of PD-1+ T cells, especially at local tumor sites. The gene discussed is PDCD1; the disease is neoplasm.